Citi analyst Patrick Donnelly raised the firm’s price target on Quest Diagnostics (DGX) to $185 from $165 and keeps a Buy rating on the shares post the Q3 report. Integrating LifeLabs was the primary driver of the updated guidance along with continued elevated utilization trends, the analyst tells investors in a research note. The firm remains constructive on Quest citing its defensive nature around an election cycle and safer out year estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $168 from $154 at Barclays
- Quest Diagnostics upgraded to Outperform from Neutral at Baird
- Early notable gainers among liquid option names on October 22nd
- Morning Movers: 3M gains and GE Aerospace falls following third quarter results
- Quest Diagnostics narrows FY24 adjusted EPS view to $8.85-$8.95 from $8.80-$9.00